Thin endometirum
Conditions
Interventions
PRP group:Patients will receive an intrauterine perfusion of approximately 2 ml of PRP on the day of HCG trigger/LH surge/anticipated endometrial conversion. This procedure will be repeated 48 hours l
G-CSF group:Patients will receive an intrauterine perfusion of 300 µg (approximately 2 ml) of G-CSF on the day of HCG trigger/LH surge/anticipated endometrial conversion, and the procedure will be rep
Sham group:A sham intrauterine infusion procedure (insertion of an intrauterine insemination catheter without actual infusion) was performed on the day of hCG administration/LH peak/endometrial transf
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Infertile couples who have received assisted reproductive treatments such as IVF/ICSI/PGT, with female partners aged between 20 and 40 years, and a Body Mass Index (BMI) ranging from 18 to 30 kg/m². 2. The first blastocyst transfer cycle following oocyte retrieval. 3. Endometrial thickness = 11 g/dL. 6. Platelet count >= 150,000/mL. 7. Hysteroscopic evaluation within the past 6 months to rule out intrauterine adhesions, multiple endometrial polyps, submucosal fibroids, or other uterine cavity abnormalities (patients who have undergone intrauterine treatment and have follow-up confirmation of nearly normal uterine cavity structure may be included); endometritis confirmed by endometrial biopsy must have been treated and tested negative. 8. The patient has signed an informed consent form and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Use of clomiphene citrate or letrozole during the embryo transfer cycle; 2. Patients with uterine malformations such as uterine septum, unicornuate uterus, or bicornuate uterus; 3. Use of donor oocytes or frozen oocytes; 4. Systemic blood disorders or coagulation abnormalities; 5. Currently receiving antiplatelet therapy (aspirin discontinued less than 7 days prior) or anticoagulant therapy; 6. Patients with hydrosalpinx who have not undergone tubal ligation or occlusion treatment; 7. Patients with a history of severe autoimmune or endocrine diseases: such as systemic lupus erythematosus, undifferentiated connective tissue disease (positive anti-nuclear antibody), hyperthyroidism, hypothyroidism, etc.; 8. History of malignant tumors; 9. Presence of large uterine fibroids (diameter > 5 cm); 10. Severe hepatic, renal, cardiac, or pulmonary dysfunction; 11. Allergy to G-CSF.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in endometrial thickness before and after intrauterine infusion;clinical pregnancy rate;Miscarriage rate;preterm birth rate;Pregnancy complications; | — |
Countries
China
Contacts
Public Contactmai qingyun
The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed